Advances in Radiation Oncology

Combining obinutuzumab with radiation for refractory DLBCL: Retrospective safety and efficacy analysis

British Journal of Haematology

Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma—outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP

Cancer Medicine

Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy

2024 ASCO Annual Meeting Abstract

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study

2024 ASCO Annual Meeting Abstract

Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study

2024 ASCO Annual Meeting Abstract

Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6

OncLive

Glofitamab plus chemotherapy meets OS end point in R/R DLBCL

CPT: Pharmacometrics & Systems Pharmacology

Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

Cancer Diagnosis & Prognosis

Clinical outcomes in patients with DLBCL treated with R-CHOP according to radiotherapy and interim PET response

Haematologica

Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: A systematic review and meta-analysis